focus -WSS

focus

author：comprehensive 2025-09-14 14:39:33 - browse：16981

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Verily hires former Apple Health leader as chief scientific officer

knowledge

hotspot

WSS

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Microsoft strikes partnership with Duke Health to advance health AI

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

CDC advisers recommend seasonal use of Pfizer RSV shot

Nearly two

For BCIs, commercial hurdles may be bigger than scientific ones

hotspot

focus

knowledge

Psychedelics group wrestles with new pharma identity

Why are Kaiser Permanente staff considering a strike?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hearing on Medicare drug price negotiation gets unusually heated

Peter Hotez and the public health issue of online harassment

What Henrietta Lacks settlement says about racism in medicine

Tori Bowie and the unacceptable rates of Black maternal death

Humana, CVS hope to turn members into patients at clinics

Jerome Adams on the need for new antivirals for Covid

Drug for rare kidney disease narrowly misses mark in clinical trial

entertainment

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

2 US Navy sailors arrested for allegedly spying for China

STAT Virtual Event: Putting AI to the Test

For BCIs, commercial hurdles may be bigger than scientific ones

Thermo Fisher plant for manufacturing gene therapies to expand

Ukraine and a new approach to mental health in war

knowledge

hotspot

hotspot

hotspot